[HTML][HTML] Oral fingolimod (FTY720) for relapsing multiple sclerosis
…, T Haas, AA Korn, G Karlsson, EW Radue - … England Journal of …, 2006 - Mass Medical Soc
Background Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation
for the treatment of relapsing multiple sclerosis. Methods We randomly assigned 281 …
for the treatment of relapsing multiple sclerosis. Methods We randomly assigned 281 …
Differential sex-independent amygdala response to infant crying and laughing in parents versus nonparents
…, G Dammann, U Von Bardeleben, EW Radue… - Biological …, 2003 - Elsevier
BACKGROUND: Animal and human studies implicate forebrain neural circuits in maternal
behavior. Here, we hypothesized that human brain response to emotional stimuli relevant for …
behavior. Here, we hypothesized that human brain response to emotional stimuli relevant for …
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability
…, CH Polman, S Borgwardt, EW Radue… - Multiple Sclerosis …, 2011 - journals.sagepub.com
Background: Although grey matter damage in multiple sclerosis is currently recognized,
determinants of grey matter volume and its relationship with disability are not yet clear. …
determinants of grey matter volume and its relationship with disability are not yet clear. …
Cerebral veins: comparative study of CT venography with intraarterial digital subtraction angiography
…, M Kolbe, A Kaim, EW Radue - American journal …, 1999 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Our objective was to compare the reliability of CT
venography with intraarterial digital subtraction angiography (DSA) in imaging cerebral venous …
venography with intraarterial digital subtraction angiography (DSA) in imaging cerebral venous …
Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients
Purpose To determine whether spinal cord atrophy differs among disease subtypes in multiple
sclerosis (MS) and whether it offers diagnostic and clinical correlative information beyond …
sclerosis (MS) and whether it offers diagnostic and clinical correlative information beyond …
Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis
Objective To examine the temporal evolution of spinal cord (SC) atrophy in multiple sclerosis
(MS), and its association with clinical progression in a large MS cohort. Methods A total of …
(MS), and its association with clinical progression in a large MS cohort. Methods A total of …
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
…, P Muraro, SM Nabavi, RS Oliveri, E Radue… - The Lancet …, 2021 - thelancet.com
Background Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells,
have been proposed as a promising therapeutic option for people with multiple sclerosis on …
have been proposed as a promising therapeutic option for people with multiple sclerosis on …
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
…, SE Libretto, T Sprenger, EW Radue - Neuroimmunology & …, 2015 - AAN Enterprises
Objectives: To determine the safety, pharmacokinetics (PK), and immunogenicity of the
recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-…
recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-…
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for …
…, SM Nabavi, PA Muraro, RS Oliveri, EW Radue… - Trials, 2019 - Springer
Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system
with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (…
with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (…
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials
…, CH Polman, J Petkau, EW Radue… - Nature Reviews …, 2012 - nature.com
Over the past 15 years, MRI lesion activity has become the accepted surrogate primary outcome
measure in proof-of-concept placebo-controlled clinical trials of new immunomodulating …
measure in proof-of-concept placebo-controlled clinical trials of new immunomodulating …
